Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002435 · ClinicalTrials.gov registry record · Phase 2

A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients

A Phase 2 study of HIV Infections, sponsored by Pharmacia.

Completed
Registry status
Phase 2
Development phase
10
Study locations

NCT00002435: Completed Phase 2 study of HIV Infections, sponsored by Pharmacia.

NCT00002435 is a Phase 2 study of HIV Infections that has completed, run by Pharmacia. The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002435, a Phase 2 study of HIV Infections, has completed, sponsored by Pharmacia.

COMPLETED
Registry status
Phase 2
Development phase
10
Study locations

Study Summary

To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its persistence when administered in combination with an antiretroviral nucleoside derivative (zidovudine; AZT). To assess the effects of THF gamma 2 on T-cells, quality of life, and progression of disease.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine
  • DRUG Thymic Humoral Factor

Study Locations (10)

California

  • UCI - Irvine
  • Southwest Community Based AIDS Treatment Group - COMBAT - Los Angeles
  • San Francisco Veterans Administration Med Ctr - San Francisco
  • Gottlieb Med Group - Sherman Oaks

Florida

  • Mem Hosp Hollywood - Hollywood
  • Goodgame Med Group - Maitland

New York

  • Chelsea Village Med Ctr - New York

Oregon

  • Portland Veterans Adm Med Ctr / Rsch & Education Grp - Portland

South Carolina

  • Dr Alfred F Burnside Jr - Columbia

Virginia

  • Infectious Disease Physicians Inc - Annandale

Trial Details

FieldValue
Phase Phase 2
Pharmacia

7 total trials

What the finished NCT00002435 record still lists

NCT00002435 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.

NCT00002435 lists 10 locations in 6 states (California, Florida, New York).

Frequently Asked Questions

What is clinical trial NCT00002435 about?

NCT00002435 is a clinical study titled "A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients". To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its persistence when administered in combination with an antiretroviral nucleoside derivative (zidovudine; AZT). To assess the e...

What is the current status of trial NCT00002435?

This trial is currently completed. It is a Phase 2 study.

What conditions does trial NCT00002435 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002435?

The interventions under investigation include: Zidovudine (DRUG), Thymic Humoral Factor (DRUG).

Who is sponsoring clinical trial NCT00002435?

This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002435 being conducted?

This trial has 10 study locations across California, Florida, New York, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002435, the US trial registry maintained by the National Library of Medicine. NCT00002435 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.